- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00735852
Decapeptyl SR With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women
A Prospective Single Centre, Single Arm, Open Label Study of the Long Term Use of a LHRA Agonist (Decapeptyl SR, 11.25mg) in Combination With Livial Add Back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre Menopausal Women
Study Overview
Detailed Description
A screening visit,will be performed and written informed consent will be obtained from the patient. In addition the patient's medical history will be checked, vital signs recorded, pain and general health questionnaires completed, blood samples collected and any prior or concomitant medications will be noted. Bone density will be determined using a DEXA scan performed in the interval between the screening and baseline visits. One month after the screening visit, patients will return to the clinic for the baseline visit. At this visit a physical examination and urine pregnancy test will be performed, vital signs measured, specific validated questionnaires on pain and endometriosis related health will be completed and symptoms of oestrogen deficiency will be documented. Patients who are still considered to be eligible for the trial will receive an injection of Decapeptyl SR 11.25 mg, and will be dispensed sufficient Livial 2.5 mg tablets to last until the next study visit. Patients will return for repeat Decapeptyl SR injections every 3 months until Month 21 at which time the last Decapeptyl SR injection will be administered. At these visits patients will also be dispensed further supplies of Livial.
Follow-up assessments will be performed during the treatment period 3, 6, 12, 18 and 24 months after the baseline visit. A final follow-up assessment will be conducted 6 months after stopping treatment. At each follow-up visit specific validated questionnaires on pain and endometriosis related health will be collected and symptoms of oestrogen deficiency will be noted. Physical examination, vital signs, bone density assessment and haematology and biochemistry analysis will be repeated at selected timepoints.
Health economic data will be collected at all study visits.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
South Yorkshire
-
Sheffield, South Yorkshire, United Kingdom, S13 8LE
- Academic Unit of Reproductive and Developmental Medicine, Jessop Wing, Tree Root Walk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- aged between 18 and 45 years inclusive
- have a clinical diagnosis of chronic cyclical pelvic pain of at least 6 months duration (with or without evidence of endometriosis)
- have had investigations for possible endometriosis within three years prior to screening visit
- had regular menstrual cycles (24-42 days) for 3 months prior to screening
- treatment with LHRHa is indicated
- must be able to understand and be willing to comply with the requirements of the protocol
Exclusion Criteria:
- treated with any LHRHa within 6 months prior to screening
- treated with danazol, gestrinone or cyproterone acetate within 6 months prior to screening
- used cyclical progesterones or combined oral contraceptives within one full menstrual cycle prior to screening
- treated with any other medication other than analgesics within 3 months prior to screening
- continuous or acyclical pelvic pain
- known metabolic bone disease
- abnormal full blood count or liver or renal function at screening or within 6 months
- unexplained vaginal bleeding
- bone mineral density age adjusted T Score of -2 or below at screening visit.
- any other medical condition or abnormality that would impact on the safety or efficacy of the study treatment
- receiving treatment with coumarin or indanedione derivatives
- known contraindication or allergy or hypersensitivity to test compounds
- pregnancy or lactation
- planning a pregnancy within 31 months of screening
- of child bearing potential and unwilling to use adequate barrier contraception for the duration of the study
- received any investigational drug therapy within 30 days prior to the study
- has previously entered the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the impact of treatment with Decapeptyl SR plus Livial on CCPP throughout the 24 month treatment period
Time Frame: baseline, month 12, month 24 and month 30
|
baseline, month 12, month 24 and month 30
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To asses effect of Decapeptyl SR on pain, disability, overall health status and quality of life
Time Frame: baseline and 3 monthly until study end
|
baseline and 3 monthly until study end
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Mostafa Metwally, Mr, Sheffield Teaching Hopsitals Trust
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STH 14404
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometriosis
-
Fabio BarraCompletedEndometriosis | Endometriosis, Rectum | Endometriosis of Vagina | Endometriosis Rectovaginal Septum | Endometriosis Pelvic | Endometriosis of ColonItaly
-
Ospedale Policlinico San MartinoCompletedEndometriosis | Bowel Endometriosis | Endometriosis, Rectum | Endometriosis ColonItaly
-
BioGene Pharmaceutical Ltd.WithdrawnSafety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis ExternaSwitzerland
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...CompletedEndometriosis | Endometriosis-related Pain | Endometriosis Thoracic | Endometriosis of Lung | Endometriosis of PleuraItaly
-
Ospedale Policlinico San MartinoCompletedEndometriosis, Rectum | Endometriosis, SigmoidItaly
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownBowel Endometriosis | Endometriosis, RectumItaly
-
Ospedale Policlinico San MartinoActive, not recruitingEndometriosis, Rectum | Endometriosis of ColonItaly
-
Catholic University of the Sacred HeartCompletedPelvic Endometriosis | Endometriosis Outside PelvisItaly
-
Semmelweis UniversityUniversity of PecsNot yet recruitingEndometriosis | Endometriosis Ovary | Endometriosis Rectovaginal Septum
-
Catholic University of the Sacred HeartCompletedPelvic Endometriosis | Endometriosis Outside PelvisItaly
Clinical Trials on Decapeptyl SR 11.25mg
-
IpsenCompletedPrecocious PubertyFrance
-
Instituto de Investigacion Sanitaria La FeCompletedFemale Urogenital DiseasesSpain
-
Benha UniversityUnknown
-
University of Alabama at BirminghamNot yet recruiting
-
G&E Herbal Biotechnology Co., LTDCompletedActinic Keratosis | Bowen's DiseaseTaiwan
-
Otsuka Pharmaceutical Development & Commercialization...Completed
-
NYU Langone HealthTerminatedIschemic Heart DiseaseUnited States
-
AVAVA, Inc.Completed
-
PfizerCompletedBacterial Infections